JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
Volume 17, Issue 2 (2025)
Iran J War Public Health 2025, 17(2): 157-168 |
Back to browse issues page
Article Type:
Subject:
Ethics code: No find
History
Received: 2025/03/2 | Accepted: 2025/06/5 | Published: 2025/06/11
Received: 2025/03/2 | Accepted: 2025/06/5 | Published: 2025/06/11
How to cite this article
Abbas R, Alsaadi J. Clinical Changes in Adiponectin, Leptin, and Some Inflammatory Parameters in Obese Patients with Type 2 Diabetes and Hypertension. Iran J War Public Health 2025; 17 (2) :157-168
URL: http://ijwph.ir/article-1-1553-en.html
URL: http://ijwph.ir/article-1-1553-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
R.K. Abbas *1, J.H.H. Alsaadi1
1- Department of Chemistry, Faculty of Science, University of Thi-Qar, Thi-Qar, Iraq
Abstract (384 Views)
Aims: This study investigated changes in adiponectin, leptin, and some inflammatory factors in the serum of obese patients with type 2 diabetes and hypertension in Thi-Qar Province, Iraq.
Materials & Methods: This clinical follow-up study was conducted at Al-Nasiriya Teaching Hospital in Thi-Qar Governorate and the biochemistry laboratory at the College of Science from August 2024 to January 2025. A total of 140 male and female subjects were included, comprising 105 patients diagnosed with obesity (body mass index≥30kg/m2) and 35 controls (body mass index<5kg/m2). The participants’ ages ranged from 35 to 65 years. They were divided into four groups, including the control group, with 35 healthy individuals, the obese group, with 35 solely obese patients, the obese diabetes mellitus group, including 35 obese patients with diabetes, and the obese hypertensive group, comprising 35 obese patients with hypertension.
Findings: There was a significant increase (p≤0.05) in leptin, high-sensitivity C-reactive protein, and interleukin-6 levels, along with a significant decrease in adiponectin levels across all patient groups compared to the control group. However, there were no significant changes (p≤0.05) in serum hypoxia-inducible factor 1-alpha levels between the patient groups and the control group. Furthermore, there was no significant difference in adiponectin, leptin, high-sensitivity C-reactive protein, IL-6, and HIF-1α serum levels between the obese diabetes group and the obese hypertensive group compared to the obese group (p≤0.05).
Conclusion: Obese patients with type 2 diabetes and hypertension exhibit significantly higher levels of LEP and inflammatory factors and significantly lower adiponectin levels compared to the controls.
Materials & Methods: This clinical follow-up study was conducted at Al-Nasiriya Teaching Hospital in Thi-Qar Governorate and the biochemistry laboratory at the College of Science from August 2024 to January 2025. A total of 140 male and female subjects were included, comprising 105 patients diagnosed with obesity (body mass index≥30kg/m2) and 35 controls (body mass index<5kg/m2). The participants’ ages ranged from 35 to 65 years. They were divided into four groups, including the control group, with 35 healthy individuals, the obese group, with 35 solely obese patients, the obese diabetes mellitus group, including 35 obese patients with diabetes, and the obese hypertensive group, comprising 35 obese patients with hypertension.
Findings: There was a significant increase (p≤0.05) in leptin, high-sensitivity C-reactive protein, and interleukin-6 levels, along with a significant decrease in adiponectin levels across all patient groups compared to the control group. However, there were no significant changes (p≤0.05) in serum hypoxia-inducible factor 1-alpha levels between the patient groups and the control group. Furthermore, there was no significant difference in adiponectin, leptin, high-sensitivity C-reactive protein, IL-6, and HIF-1α serum levels between the obese diabetes group and the obese hypertensive group compared to the obese group (p≤0.05).
Conclusion: Obese patients with type 2 diabetes and hypertension exhibit significantly higher levels of LEP and inflammatory factors and significantly lower adiponectin levels compared to the controls.
Keywords:
References
1. Lin X, Li H. Obesity: Epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12:706978. [Link] [DOI:10.3389/fendo.2021.706978]
2. Kaplan LM, Apovian CM, Ard JD, Allison DB, Aronne LJ, Batterham RL, et al. Assessing the state of obesity care: Quality, access, guidelines, and standards. Obes Sci Pract. 2024;10(4):e765. [Link] [DOI:10.1002/osp4.765]
3. Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020;13:3611-6. [Link] [DOI:10.2147/DMSO.S275898]
4. Smith GI, Polidori DC, Yoshino M, Kearney ML, Patterson BW, Mittendorfer B, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. J Clin Invest. 2020;130(6):3305-14. [Link] [DOI:10.1172/JCI136756]
5. Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549-64. [Link] [DOI:10.1161/CIRCRESAHA.119.315896]
6. Wang X, Xu M, Li Y. Adipose tissue aging and metabolic disorder, and the impact of nutritional interventions. Nutrients. 2022;14(15):3134. [Link] [DOI:10.3390/nu14153134]
7. Shariq OA, McKenzie TJ. Obesity-related hypertension: A review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80-93. [Link] [DOI:10.21037/gs.2019.12.03]
8. Flack JM, Calhoun D, Schiffrin EL. The new ACC/AHA hypertension guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Am J Hypertens. 2018;31(2):133-5. [Link] [DOI:10.1093/ajh/hpx207]
9. Lambert EA, Esler MD, Schlaich MP, Dixon J, Eikelis N, Lambert GW. Obesity-associated organ damage and sympathetic nervous activity. Hypertension. 2019;73(6):1150-9. [Link] [DOI:10.1161/HYPERTENSIONAHA.118.11676]
10. Saxton SN, Clark BJ, Withers SB, Eringa EC, Heagerty AM. Mechanistic links between obesity, diabetes, and blood pressure: Role of perivascular adipose tissue. Physiol Rev. 2019;99(4):1701-63. [Link] [DOI:10.1152/physrev.00034.2018]
11. Schütten MT, Houben AJ, De Leeuw PW, Stehouwer CD. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32(3):197-209. [Link] [DOI:10.1152/physiol.00037.2016]
12. Mohamed MS, Youssef TM, Abdullah EE, Ahmed AE. Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease. Egypt Liver J. 2021;11:78. [Link] [DOI:10.1186/s43066-021-00134-3]
13. Jung D, Bucher F, Ryu S, Jeong J, Lee BY, Jeong Y, et al. An adiponectin receptor agonist antibody stimulates glucose uptake and fatty-acid oxidation by activating AMP-activated protein kinase. Cytokine. 2020;126:154863. [Link] [DOI:10.1016/j.cyto.2019.154863]
14. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-95. [Link] [DOI:10.1038/nm788]
15. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: Role and clinical implication. Front Endocrinol. 2021;12:585887. [Link] [DOI:10.3389/fendo.2021.585887]
16. Ambad R, Jha RK, Chandi DH, Hadke S. Association of leptin in diabetes mellitus and obesity. Res J Pharm Technol. 2020;13(12):6295-9. [Link] [DOI:10.5958/0974-360X.2020.01095.1]
17. Al Sheikh MH. The determinants of leptin levels in diabetic and nondiabetic Saudi males. Int J Endocrinol. 2017;2017:3506871. [Link] [DOI:10.1155/2017/3506871]
18. Awede B, Adovoekpe D, Adehan G, MacFarlane NG, Azonbakin S, Dossou E, et al. Adiponectin, in contrast to leptin, is not associated with body mass index, waist circumference and HOMA-IR in subjects of a west-African population. Physiol Rep. 2018;6(11):e13718. [Link] [DOI:10.14814/phy2.13718]
19. Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V. Role of leptin in inflammation and vice versa. Int J Mol Sci. 2020;21(16):5887. [Link] [DOI:10.3390/ijms21165887]
20. Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: Underlying mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019;12:191-8. [Link] [DOI:10.2147/DMSO.S182406]
21. Wang C, Chang L, Wang J, Xia L, Cao L, Wang W, et al. Leptin and risk factors for atherosclerosis: A review. Medicine. 2023;102(46):e36076. [Link] [DOI:10.1097/MD.0000000000036076]
22. Liu HH, Cao YX, Sun D, Jin JL, Zhang HW, Guo YL, et al. High-sensitivity C-reactive protein and hypertension: Combined effects on coronary severity and cardiovascular outcomes. Hypertens Res. 2019;42(11):1783-93. [Link] [DOI:10.1038/s41440-019-0293-8]
23. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945-51. [Link] [DOI:10.1001/jama.290.22.2945]
24. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122. [Link] [DOI:10.1186/s12933-018-0762-4]
25. Varra FN, Varras M, Varra VK, Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review). Mol Med Rep. 2024;29(6):95. [Link] [DOI:10.3892/mmr.2024.13219]
26. Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728-46. [Link] [DOI:10.1161/CIRCRESAHA.121.319077]
27. Lin W, Song H, Shen J, Wang J, Yang Y, Yang Y, et al. Functional role of skeletal muscle-derived interleukin-6 and its effects on lipid metabolism. Front Physiol. 2023;14:1110926. [Link] [DOI:10.3389/fphys.2023.1110926]
28. Metcalfe RD, Putoczki TL, Griffin MDW. Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: Focus on interleukin 11. Front Immunol. 2020;11:1424. [Link] [DOI:10.3389/fimmu.2020.01424]
29. Marofi F, Achmad H, Bokov D, Abdelbasset WK, Alsadoon Z, Chupradit S, et al. Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Res Ther. 2022;13(1):140. [Link] [DOI:10.1186/s13287-022-02819-x]
30. Malkov MI, Lee CT, Taylor CT. Regulation of the hypoxia-inducible factor (HIF) by pro-inflammatory cytokines. Cells. 2021;10(9):2340. [Link] [DOI:10.3390/cells10092340]
31. Gramley F, Lorenzen J, Jedamzik B, Gatter K, Koellensperger E, Munzel T, et al. Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol. 2010;19(2):102-11. [Link] [DOI:10.1016/j.carpath.2008.11.001]
32. Qiu B, Yuan P, Du X, Jin H, Du J, Huang Y. Hypoxia inducible factor-1α is an important regulator of macrophage biology. Heliyon. 2023;9(6):e17167. [Link] [DOI:10.1016/j.heliyon.2023.e17167]
33. Liu W, Zhou X, Li Y, Zhang S, Cai X, Zhang R, et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: A population-based study. Medicine. 2020;99(6):e19052. [Link] [DOI:10.1097/MD.0000000000019052]
34. Ghoshal K, Chatterjee T, Chowdhury S, Sengupta S, Bhattacharyya M. Adiponectin genetic variant and expression coupled with lipid peroxidation reveal new Signatures in diabetic dyslipidemia. Biochem Genet. 2021;59(3):781-98. [Link] [DOI:10.1007/s10528-021-10030-5]
35. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321. [Link] [DOI:10.3390/ijms18061321]
36. Baldelli S, Aiello G, Mansilla Di Martino E, Campaci D, Muthanna FMS, Lombardo M. The role of adipose tissue and nutrition in the regulation of adiponectin. Nutrients. 2024;16(15):2436. [Link] [DOI:10.3390/nu16152436]
37. Wu O, Lu X, Leng J, Zhang X, Liu W, Yang F, et al. Reevaluating adiponectin's impact on obesity hypertension: A Chinese case-control study. BMC Cardiovasc Disord. 2024;24(1):208. [Link] [DOI:10.1186/s12872-024-03865-4]
38. Masi S, Ambrosini S, Mohammed SA, Sciarretta S, Lüscher TF, Paneni F, et al. Epigenetic remodeling in obesity-related vascular disease. Antioxid Redox Signal. 2021;34(15):1165-99. [Link] [DOI:10.1089/ars.2020.8040]
39. Peng J, Chen Q, Wu C. The role of adiponectin in cardiovascular disease. Cardiovasc Pathol. 2023;64:107514. [Link] [DOI:10.1016/j.carpath.2022.107514]
40. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: Correction after ventricular assist device implantation. Circ Heart Fail. 2012;5(3):340-8. [Link] [DOI:10.1161/CIRCHEARTFAILURE.111.964031]
41. Jiang K, Luan H, Pu X, Wang M, Yin J, Gong R. Association between visceral adiposity index and insulin resistance: A cross-sectional study based on US adults. Front Endocrinol. 2022;13:921067. [Link] [DOI:10.3389/fendo.2022.921067]
42. Hamzeh B, Pasdar Y, Mirzaei N, Faramani RS, Najafi F, Shakiba E, et al. Visceral adiposity index and atherogenic index of plasma as useful predictors of risk of cardiovascular diseases: Evidence from a cohort study in Iran. Lipids Health Dis. 2021;20(1):82. [Link] [DOI:10.1186/s12944-021-01505-w]
43. Qin Y, Qiao Y, Wang D, Li M, Yang Z, Li L, et al. Visceral adiposity index is positively associated with fasting plasma glucose: A cross-sectional study from National Health and Nutrition Examination Survey 2017-2020. BMC Public Health. 2023;23(1):313. [Link] [DOI:10.1186/s12889-023-15231-8]
44. Liao PJ, Ting MK, Wu IW, Chen SW, Yang NI, Hsu KH. Higher leptin-to-adiponectin ratio strengthens the association between body measurements and occurrence of type 2 diabetes mellitus. Front Public Health. 2021;9:678681. [Link] [DOI:10.3389/fpubh.2021.678681]
45. Ayina CN, Noubiap JJ, Etoundi Ngoa LS, Boudou P, Gautier JF, Mengnjo MK, et al. Association of serum leptin and adiponectin with anthropomorphic indices of obesity, blood lipids and insulin resistance in a Sub-Saharan African population. Lipids Health Dis. 2016;15:96. [Link] [DOI:10.1186/s12944-016-0264-x]
46. Lei X, Qiu S, Yang G, Wu Q. Adiponectin and metabolic cardiovascular diseases: Therapeutic opportunities and challenges. Genes Dis. 2022;10(4):1525-36. [Link] [DOI:10.1016/j.gendis.2022.10.018]
47. Kaze AD, Musani SK, Bidulescu A, Correa A, Golden SH, Bertoni AG, et al. Plasma adiponectin and blood pressure progression in African Americans: The Jackson heart study. Am J Hypertens. 2021;34(11):1163-70. [Link] [DOI:10.1093/ajh/hpab101]
48. Adela R, Reddy PNC, Ghosh TS, Aggarwal S, Yadav AK, Das B, et al. Serum protein signature of coronary artery disease in type 2 diabetes mellitus. J Transl Med. 2019;17:17. [Link] [DOI:10.1186/s12967-018-1755-5]
49. Gul E, Gul Y, Yıldırım E, Pepele MS, Yıldız M, Bozdemir MN, et al. The diagnostic role of adiponectin in pulmonary embolism. Biomed Res Int. 2016;2016:6121056. [Link] [DOI:10.1155/2016/6121056]
50. Straub LG, Scherer PE. Metabolic messengers: Adiponectin. Nat Metab. 2019;1(3):334-9. [Link] [DOI:10.1038/s42255-019-0041-z]
51. Bhat H, Bhat JA, Bhat MH, Rashid M, Jan R, Afroze D. Leptin in obesity and hypertension. Arter Hypertens. 2022;26(1):26-31. [Link] [DOI:10.5603/AH.a2022.0003]
52. Onyemelukwe OU, Ogoina D, Onyemelukwe GC. Leptin concentrations in type 2 diabetes and non-diabetes Nigerian-Africans. Am J Cardiovasc Dis. 2020;10(4):444-54. [Link]
53. Kumar V, Evans LC, Kurth T, Yang C, Wollner C, Nasci V, et al. Therapeutic suppression of mTOR (Mammalian Target of Rapamycin) signaling prevents and reverses salt-induced hypertension and kidney injury in Dahl salt-sensitive rats. Hypertension. 2019;73(3):630-9. [Link] [DOI:10.1161/HYPERTENSIONAHA.118.12378]
54. Hu F, Rao M, Zhang M, Meng Q, Wan M, Zhang X, et al. Long non-coding RNA profiles in plasma exosomes of patients with gastric high-grade intraepithelial neoplasia. Exp Ther Med. 2022;23(1):1. [Link] [DOI:10.3892/etm.2021.10923]
55. Guarino D, Nannipieri M, Iervasi G, Taddei S, Bruno RM. The role of the autonomic nervous system in the pathophysiology of obesity. Front Physiol. 2017;8:665. [Link] [DOI:10.3389/fphys.2017.00665]
56. Paiva ES, Andretta A, Batista ED, Lobo MMMT, Miranda RC, Nisihara R, et al. Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity. Arch Endocrinol Metab. 2017;61(3):249-56. [Link] [DOI:10.1590/2359-3997000000248]
57. Aisike G, Kuerbanjiang M, Muheyati D, Zaibibuli K, Lv MX, Han J. Correlation analysis of obesity phenotypes with leptin and adiponectin. Sci Rep. 2023;13(1):17718. [Link] [DOI:10.1038/s41598-023-43550-8]
58. Ellacott KL, Halatchev IG, Cone RD. Interactions between gut peptides and the central melanocortin system in the regulation of energy homeostasis. Peptides. 2006;27(2):340-9. [Link] [DOI:10.1016/j.peptides.2005.02.031]
59. Hajishizari S, Imani H, Mehranfar S, Saeed Yekaninejad M, Mirzababaei A, Clark CCT, et al. The association of appetite and hormones (leptin, ghrelin, and Insulin) with resting metabolic rate in overweight/obese women: A case-control study. BMC Nutr. 2022;8(1):37. [Link] [DOI:10.1186/s40795-022-00531-w]
60. Wabitsch M, Funcke JB, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin KM, et al. Biologically inactive leptin and early-onset extreme obesity. N Engl J Med. 2015;372(1):48-54. [Link] [DOI:10.1056/NEJMoa1406653]
61. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566-81. [Link] [DOI:10.1152/ajpregu.00180.2013]
62. Hernandez V, Kaur K, ElSharief MW, Al Hajaj SW, Ebrahim AM, Razack M, et al. The new kid on the block: The mechanisms of action of hyperleptinemia in coronary artery disease and atherosclerosis. Cureus. 2021;13(6):e15766. [Link] [DOI:10.7759/cureus.15766]
63. Khaki-Khatibi F, Shademan B, Gholikhani-Darbroud R, Nourazarian A, Radagdam S, Porzour M. Gene polymorphism of leptin and risk for heart disease, obesity, and high BMI: A systematic review and pooled analysis in adult obese subjects. Horm Mol Biol Clin Investig. 2022;44(1):11-20. [Link] [DOI:10.1515/hmbci-2022-0020]
64. Najam SS, Awan FR, Islam M, Khurshid M, Khan AR, Siddique E, et al. Leptin correlation with obesity, diabetes and gender in a population from Faisalabad, Pakistan. Arch Med. 2016;8(5):1-5. [Link] [DOI:10.21767/1989-5216.1000169]
65. Fabian UA, Charles-Davies MA, Adebusuyi JR, Ebesunun MO, Ajobo BM, Hassan OO, et al. Leptin concentrations in African blacks with metabolic syndrome and type 2 diabetes mellitus. J US China Med Sci. 2011;8(8):493-500. [Link]
66. Uludağ B, Solmaz H, Alihanoğlu Yİ, Kılıç İD, Enli Y. The relationship of body mass index with insulin resistance, hs-CRP, and Lp (a) levels in female gender. Int J Cardiovasc Acad. 2023;9(10):3-8. [Link] [DOI:10.4274/ijca.76486]
67. Marfianti E, Andriyanto E. The correlation between cardiometabolic risks and high-sensitivity c reactive protein (Hs-CRP) levels in serum among young adults with overweight and obesity. Proceedings of the 3rd International Conference on Cardiovascular Diseases. Dordrecht: Atlantis Press; 2022. p. 117-26. [Link] [DOI:10.2991/978-94-6463-048-0_14]
68. Mulyamin W, Kurniawan LB, Adnan E, Widaningsih Y, Idris I, Santoso A, et al. Body mass index as the most influential factor of high-sensitivity C-reactive protein in non-diabetic adults. UNIVERSA MEDICINA. 2021;40(1):22-8. [Link] [DOI:10.18051/UnivMed.2021.v40.22-28]
69. Rattu C, Bolang AS, Kawengian SE. Relationship of body mass index with high sensitivity c-reactive protein serum levels in obese and non-obese students at the faculty of medicine, Sam Ratulangi University, Manado. eBiomedik. 2013;1(1). [Indonesian] [Link] [DOI:10.35790/ebm.1.1.2013.1610]
70. Ramos-Arellano LE, Matia-Garcia I, Marino-Ortega LA, Castro-Alarcón N, Muñoz-Valle JF, Salgado-Goytia L, et al. Obesity, dyslipidemia, and high blood pressure are associated with cardiovascular risk, determined using high-sensitivity C-reactive protein concentration, in young adults. J Int Med Res. 2020;48(12):300060520980596. [Link] [DOI:10.1177/0300060520980596]
71. Seo YH, Shin HY. Relationship between hs-CRP and HbA1c in diabetes mellitus patients: 2015-2017 Korean national health and nutrition examination survey. Chonnam Med J. 2021;57(1):62-7. [Link] [DOI:10.4068/cmj.2021.57.1.62]
72. Son NE. Influence of ferritin levels and inflammatory markers on HbA1c in the Type 2 Diabetes mellitus patients. Pak J Med Sci. 2019;35(4):1030-5. [Link] [DOI:10.12669/pjms.35.4.1003]
73. Mesa RA, Damas OM, Schneiderman N, Palacio AM, Gallo LC, Talavera GA, et al. Association between high-sensitivity c-reactive protein and metabolic syndrome among hispanic/latino participants of the hispanic community health study/study of Latinos. Metab Syndr Relat Disord. 2024;22(5):327-36. [Link] [DOI:10.1089/met.2023.0298]
74. Shen Q, He T, Li T, Szeto IM, Mao S, Zhong W, et al. Synergistic effects of overweight/obesity and high hemoglobin A1c status on elevated high-sensitivity C-reactive protein in Chinese adults: A cross-sectional study. Front Nutr. 2023;10:1156404. [Link] [DOI:10.3389/fnut.2023.1156404]
75. Zhang R, Dong SY, Wang F, Ma C, Zhao XL, Zeng Q, et al. Associations between body composition indices and metabolic disorders in Chinese adults: A cross-sectional observational study. Chin Med J. 2018;131(4):379-88. [Link] [DOI:10.4103/0366-6999.225059]
76. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines. ISRN Inflamm. 2013;2013:139239. [Link] [DOI:10.1155/2013/139239]
77. Bosch-Sierra N, Grau-Del Valle C, Hermenejildo J, Hermo-Argibay A, Salazar JD, Garrido M, et al. The impact of weight loss on inflammation, oxidative stress, and mitochondrial function in subjects with obesity. Antioxidants. 2024;13(7):870. [Link] [DOI:10.3390/antiox13070870]
78. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31-55. [Link] [DOI:10.1016/j.immuni.2021.12.013]
79. Zhang H, Dhalla NS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci. 2024;25(2):1082. [Link] [DOI:10.3390/ijms25021082]
80. Ismail MI, Gabr MG, Kamal NM, Elokely AM, El-Shishtawy SH. Study of serum omentin-1 and IL-6 in patients with obesity, hypertension and hypertensive nephropathy. Egypt J Hosp Med. 2024;95. [Link] [DOI:10.21608/ejhm.2024.352946]
81. El-Mikkawy D, El-Sadek M, El-Badawy M, Samaha D. Circulating level of interleukin-6 in relation to body mass indices and lipid profile in Egyptian adults with overweight and obesity. Egypt Rheumatol Rehabil. 2020;47:7. [Link] [DOI:10.1186/s43166-020-00003-8]
82. Baikpour M, Baikpour M, Hosseini M, Sarveazad A. Variations in levels of interleukins and adiponectin in normal and obese adults; A case-control study. J Med Physiol. 2017;2(2):56-62. [Link]
83. Pourhassan M, Babel N, Sieske L, Westhoff TH, Wirth R. Inflammatory cytokines and appetite in older hospitalized patients. Appetite. 2021;166:105470. [Link] [DOI:10.1016/j.appet.2021.105470]
84. Oussaada SM, Kilicarslan M, De Weijer BA, Gilijamse PW, Şekercan A, Virtue S, et al. Tissue-specific inflammation and insulin sensitivity in subjects with obesity. Diabetes Res Clin Pract. 2024;211:111663. [Link] [DOI:10.1016/j.diabres.2024.111663]
85. Liu R, Nikolajczyk BS. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond. Front Immunol. 2019;10:1587. [Link] [DOI:10.3389/fimmu.2019.01587]
86. Al-Hashem F, Al-Humayed S, Amin SN, Kamar SS, Mansy SS, Hassan S, et al. Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations. J Cell Physiol. 2019;234(6):9328-37. [Link] [DOI:10.1002/jcp.27616]
87. Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M, et al. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2016;7(1):873-84. [Link] [DOI:10.18632/oncotarget.6418]
88. Wu J, Chu Y, Jiang Z, Yu Q. Losartan protects against intermittent hypoxia-induced peritubular capillary loss by modulating the renal renin-angiotensin system and angiogenesis factors. ACTA BIOCHIMICA ET BIOPHYSICA SINICA. 2020;52(1):38-48. [Link] [DOI:10.1093/abbs/gmz136]
89. Van Ginkel S, Ruoss S, Valdivieso P, Degens H, Waldron S, De Haan A, et al. ACE inhibition modifies exercise-induced pro-angiogenic and mitochondrial gene transcript expression. Scand J Med Sci Sports. 2016;26(10):1180-7. [Link] [DOI:10.1111/sms.12572]
90. Qin C, Hu Z, Shi Y, Wu H, Ma J, Li J. Association of serum HIF-1α levels with coronary artery calcification in patients of non-dialysis chronic kidney disease. Sci Rep. 2024;14(1):29031. [Link] [DOI:10.1038/s41598-024-79393-0]
91. Brooks JT, Elvidge GP, Glenny L, Gleadle JM, Liu C, Ragoussis J, et al. Variations within oxygen-regulated gene expression in humans. J Appl Physiol. 2009;106(1):212-20. [Link] [DOI:10.1152/japplphysiol.90578.2008]